* age \<18 years * history of pancreatitis * history of multiple endocrine neoplasia or medullary thyroid cancer * current use of a glp-1 receptor agonist \[use of a dpp-4 inhibitor is allowed\] * positive beta-hcg (pregnancy test is mandated with baseline bloodwork for all female subjects ≤50 years of age * breastfeeding, if they intend to continue breastfeeding * elevation of serum lipase, direct (conjugated) bilirubin, or alkaline phosphatase (alp) more than 3x the upper limit of normal on baseline bloodwork * history of decompensated heart failure with reduced ejection fraction (\<35%) within 90 days, or known stable nyha class iv heart failure prior to their covid-19 illness * imminent mechanical ventilation or death * o2 therapy with high flow nasal cannula at fio2 \>50% or already on mechanical ventilation * any marker of hemodynamic instability at baseline defined as persistent sbp \<90 mmhg after rehydration, or \> 220 mmhg after receiving routine antihypertensive therapy, or hr \<50 bpm or \> 140 bpm after rehydration. * inability to provide informed consent from patient or substitute decision maker (sdm)

* age \<18 years * history of pancreatitis * history of multiple endocrine neoplasia or medullary thyroid cancer * current use of a glp-1 receptor agonist \[use of a dpp-4 inhibitor is allowed\] * positive beta-hcg (pregnancy test is mandated with baseline bloodwork for all female subjects ≤50 years of age * breastfeeding, if they intend to continue breastfeeding * elevation of serum lipase, direct (conjugated) bilirubin, or alkaline phosphatase (alp) more than 3x the upper limit of normal on baseline bloodwork * history of decompensated heart failure with reduced ejection fraction (\<35%) within 90 days, or known stable nyha class iv heart failure prior to their covid-19 illness * imminent mechanical ventilation or death * o2 therapy with high flow nasal cannula at fio2 \>50% or already on mechanical ventilation * any marker of hemodynamic instability at baseline defined as persistent sbp \<90 mmhg after rehydration, or \> 220 mmhg after receiving routine antihypertensive therapy, or hr \<50 bpm or \> 140 bpm after rehydration. * inability to provide informed consent from patient or substitute decision maker (sdm)

age <18 years history of pancreatitis history of multiple endocrine neoplasia or medullary thyroid cancer current use of a glp-1 receptor agonist [use of a dpp-4 inhibitor is allowed] positive beta-hcg (pregnancy test is mandated with baseline bloodwork for all female subjects ≤50 years of age breastfeeding, if they intend to continue breastfeeding elevation of serum lipase, direct (conjugated) bilirubin, or alkaline phosphatase (alp) more than 3x the upper limit of normal on baseline bloodwork history of decompensated heart failure with reduced ejection fraction (<35%) within 90 days, or known stable nyha class iv heart failure prior to their covid-19 illness imminent mechanical ventilation or death o2 therapy with high flow nasal cannula at fio2 >50% or already on mechanical ventilation any marker of hemodynamic instability at baseline defined as persistent sbp <90 mmhg after rehydration, or > 220 mmhg after receiving routine antihypertensive therapy, or hr <50 bpm or > 140 bpm after rehydration. inability to provide informed consent from patient or substitute decision maker (sdm)

age <18 years history of pancreatitis history of multiple endocrine neoplasia or medullary thyroid cancer current use of a glp-1 receptor agonist [use of a dpp-4 inhibitor is allowed] positive beta-hcg (pregnancy test is mandated with baseline bloodwork for all female subjects ≤50 years of age breastfeeding, if they intend to continue breastfeeding elevation of serum lipase, direct (conjugated) bilirubin, or alkaline phosphatase (alp) more than 3x the upper limit of normal on baseline bloodwork history of decompensated heart failure with reduced ejection fraction (<35%) within 90 days, or known stable nyha class iv heart failure prior to their covid-19 illness imminent mechanical ventilation or death o2 therapy with high flow nasal cannula at fio2 >50% or already on mechanical ventilation any marker of hemodynamic instability at baseline defined as persistent sbp <90 mmhg after rehydration, or > 220 mmhg after receiving routine antihypertensive therapy, or hr <50 bpm or > 140 bpm after rehydration. inability to provide informed consent from patient or substitute decision maker (sdm)

- age <18 years - history of pancreatitis - history of multiple endocrine neoplasia or medullary thyroid cancer - current use of a glp-1 receptor agonist [use of a dpp-4 inhibitor is allowed] - positive beta-hcg (pregnancy test is mandated with baseline bloodwork for all female subjects ≤50 years of age - elevation of serum lipase, direct (conjugated) bilirubin, or alkaline phosphatase (alp) more than 3x the upper limit of normal on baseline bloodwork - history of decompensated heart failure with reduced ejection fraction (<35%) within 90 days, or known stable nyha class iv heart failure prior to their covid-19 illness - imminent mechanical ventilation or death - o2 therapy >4 lpm by nasal cannula or mask or already receiving non-invasive mechanical ventilation on enrolment - any marker of hemodynamic instability at baseline defined as persistent sbp <90 mmhg after rehydration, or > 220 mmhg after receiving routine antihypertensive therapy, or hr <50 bpm or > 140 bpm after rehydration. - inability to provide informed consent

- age <18 years - history of pancreatitis - history of multiple endocrine neoplasia or medullary thyroid cancer - current use of a glp-1 receptor agonist [use of a dpp-4 inhibitor is allowed] - positive beta-hcg (pregnancy test is mandated with baseline bloodwork for all female subjects ≤50 years of age - elevation of serum lipase, direct (conjugated) bilirubin, or alkaline phosphatase (alp) more than 3x the upper limit of normal on baseline bloodwork - history of decompensated heart failure with reduced ejection fraction (<35%) within 90 days, or known stable nyha class iv heart failure prior to their covid-19 illness - imminent mechanical ventilation or death - o2 therapy >4 lpm by nasal cannula or mask or already receiving non-invasive mechanical ventilation on enrolment - any marker of hemodynamic instability at baseline defined as persistent sbp <90 mmhg after rehydration, or > 220 mmhg after receiving routine antihypertensive therapy, or hr <50 bpm or > 140 bpm after rehydration. - inability to provide informed consent